

September 25, 2002

Dr. Hans Roethig  
Philip Morris  
Box 26603  
Richmond, Virginia 23261

Dear Dr. Roethig:

It was a pleasure to see you again at the Investigators' Meeting in Philadelphia. I apologize for taking so long in writing to you but, immediately after Philadelphia, I left for the European Respiratory Society meetings in Stockholm. They were, as usual, very interesting.

I have no doubt the study will be an exceedingly interesting one and look forward to participating both as an investigator and as an active participant on the writing committee.

At the time of the meeting in Philadelphia, we did not have much of an opportunity to discuss plans with respect to writing. Obviously, I would welcome the opportunity to do this in the near future. Perhaps we could also continue our ongoing discussion on the use of biomarkers in the lung in the assessment of harm reduction products.

In any case, it was good to see you. I am very enthusiastic about this study as it promises to be exceedingly informative. There also will be, I am quite sure, a number of interesting hurdles, both scientific and political.

Yours sincerely,



Stephen I. Rennard, M.D.  
Larson Professor  
Pulmonary and Critical Care Medicine Section  
Department of Internal Medicine  
University of Nebraska Medical Center